The General Pharmaceutical Council (GPhC) has warned that pharmacies offering weight‑management medicines face escalating regulatory scrutiny, following a detailed review of inspections and concerns across Great Britain. The report identifies significant weaknesses in governance, prescribing practice, advertising compliance and medicine supply—issues that are now directly contributing to enforcement action and, in some cases, fitness to practise sanctions.

The review, covering inspection findings and more than 1,300 concerns, shows that weight‑management services—particularly those involving GLP‑1 receptor agonists—have become a high‑risk area for regulatory intervention. Pharmacies delivering these services without robust clinical and operational safeguards are increasingly likely to face improvement plans, conditions on registration, or referral for fitness to practise investigation.

Governance failures remain a major driver of regulatory risk

The GPhC found that many pharmacies lacked adequate risk assessments, up‑to‑date SOPs and clear clinical oversight. Standard 1.1 (risk management) and Standard 4.2 (safe and effective service delivery) were among the most frequently unmet standards.

Inspectors reported inconsistent documentation, poor record‑keeping, and limited evidence of structured follow‑up—issues that undermine safe prescribing and expose pharmacies to enforcement action.

Prescribing concerns and unsafe supply practices

Prescribing practice was the single largest area of concern. The GPhC identified repeated failures in:

• Independent verification of BMI and clinical suitability
• Appropriate dose titration and monitoring
• Communication with GPs
• Managing adverse effects and discontinuation
• Ensuring vulnerable groups are protected

Dispensing errors, incorrect quantities, expired stock and unsafe delivery practices—including cold‑chain failures—were also highlighted as recurring risks.

Advertising breaches continue despite clear regulatory warnings

The review notes widespread non‑compliance with advertising rules, including unlawful promotion of prescription‑only medicines, influencer marketing, discount codes and direct‑to‑consumer advertising. These breaches fall squarely within the scope of the joint CAP/MHRA/GPhC enforcement notice and have already triggered regulatory action.

Customer service issues now viewed as regulatory failings

Poor accessibility—such as non‑functioning phone lines, unanswered emails and delayed refunds—was a major theme in the concerns reviewed. The GPhC emphasises that inadequate communication is not merely a commercial issue but a standards compliance issue, particularly where it affects continuity of care.

Enforcement action and the link to fitness to practise sanctions

The GPhC has made clear that enforcement action taken against a pharmacy or pharmacy owner can escalate into fitness to practise proceedings for individual registrants.  According to legal commentary from GPhC defence specialists, enforcement action may lead to fitness to practise sanctions where:

• A pharmacist’s actions contributed to systemic failures
• There is evidence of unsafe or inappropriate supply
• Governance failures reflect a lack of professional judgement
• A registrant failed to act on known risks or concerns

Sanctions can include conditions, suspension or removal from the register.  For pharmacy owners, this reinforces the need for strong governance, documented oversight and proactive risk management.

What pharmacies should do now

The GPhC expects pharmacies to:

• Strengthen governance and maintain regularly reviewed risk assessments
• Ensure robust clinical oversight of prescribing and supply
• Verify BMI and eligibility independently
• Improve documentation and follow‑up
• Audit cold‑chain processes and delivery arrangements
• Remove unlawful advertising and ensure compliance with the enforcement notice
• Provide accessible, responsive customer service
• Conduct due diligence on third‑party prescribers and suppliers

Pharmacies that fail to address these areas risk enforcement action that may escalate to fitness to practise proceedings.

Kings View Chambers: specialist fitness to practise defence

With over 30 years of combined experience, Kings View Chambers is recognised as one of the leading teams in fitness to practise defence. We understand that fitness to practise investigations are not just regulatory processes—they are deeply personal, often stressful experiences that can affect your career, wellbeing, and reputation.

Our approach is built on:

• Expertise – decades of specialist experience in GMC and MPTS defence.
• Empathy – recognising the anxiety and uncertainty doctors face during investigations.
• Excellence – consistently rated ‘excellent’ by clients for our commitment, clarity, and results.
• Support – guiding you through every stage of the process with professionalism and care.

Contact us today for a free, no-obligation telephone consultation and speak directly with one of the most experienced fitness to practise defence barristers. You deserve expert support—especially when the stakes are this high.